Quantum BioPharma Ltd.QNTM
Key ratios
ROA
-51.8%TTM
2025
-67.6%2024
-58.3%2023
-43.0%
ROE
-621.5%TTM
2025
-346.9%2024
-127.8%2023
-83.9%
Recent news
Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target
Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
Quantum BioPharma Ltd. (NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment
Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange
Quantum Biopharma Provides Corporate Update
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
Quantum BioPharma Announces Closing of Debt Settlement
Track QNTM in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer